Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says

MT Newswires Live

Yesterday

Amgen's (AMGN) Q3 results should reflect continued momentum across the company's growth portfolio and offer clarity on the anticipated sequential rise in operating expenses, BofA Securities said in a Monday research report.

BofA said it expects Q3 adjusted EPS of $5.70 per share on revenue of $10.02 billion. The company is due to report Q3 results on Nov. 3.

The brokerage said it also looks for clarity on the investment outlook heading into 2027 and maintained a measured view on pipeline execution.

BofA said it expects updates on the pricing and adoption durability of Pavblu to treat certain retinal eye conditions amid growing competition. It added that successive biosimilar launches could offset erosion in mature products.

The firm reiterated its underperform rating on the stock and increased its price target to $328 per share from $317.

Price: 415.34, Change: +0.47, Percent Change: +0.11

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigermarketl.com/news/2674580515"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2674580515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2674580515?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-12 22:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674580515","market":"sh","top_or_hot":-1,"title":"Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says","media":"MT Newswires Live","content":"<html><body><p> Amgen's (AMGN) Q3 results should reflect continued momentum across the company's growth portfolio and offer clarity on the anticipated sequential rise in operating expenses, BofA Securities said in a Monday research report.</p><p>BofA said it expects Q3 adjusted EPS of $5.70 per share on revenue of $10.02 billion. The company is due to report Q3 results on Nov. 3.</p><p>The brokerage said it also looks for clarity on the investment outlook heading into 2027 and maintained a measured view on pipeline execution.</p><p>BofA said it expects updates on the pricing and adoption durability of Pavblu to treat certain retinal eye conditions amid growing competition. It added that successive biosimilar launches could offset erosion in mature products.</p><p>The firm reiterated its underperform rating on the stock and increased its price target to $328 per share from $317.</p><p>Price: 415.34, Change: +0.47, Percent Change: +0.11</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen's Q3 Results Should Reflect Continued Commercial Momentum, BofA Securities Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-12 22:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Amgen's (AMGN) Q3 results should reflect continued momentum across the company's growth portfolio and offer clarity on the anticipated sequential rise in operating expenses, BofA Securities said in a Monday research report.</p><p>BofA said it expects Q3 adjusted EPS of $5.70 per share on revenue of $10.02 billion. The company is due to report Q3 results on Nov. 3.</p><p>The brokerage said it also looks for clarity on the investment outlook heading into 2027 and maintained a measured view on pipeline execution.</p><p>BofA said it expects updates on the pricing and adoption durability of Pavblu to treat certain retinal eye conditions amid growing competition. It added that successive biosimilar launches could offset erosion in mature products.</p><p>The firm reiterated its underperform rating on the stock and increased its price target to $328 per share from $317.</p><p>Price: 415.34, Change: +0.47, Percent Change: +0.11</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2674580515","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2674580515","pubTimestamp":1791815973,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amgen's  Q3 results should reflect continued momentum across the company's growth portfolio and offer clarity on the anticipated sequential rise in operating expenses, BofA Securities said in a Monday research report.BofA said it expects Q3 adjusted EPS of $5.70 per share on revenue of $10.02 billion. The company is due to report Q3 results on Nov. 3.The brokerage said it also looks for clarity on the investment outlook heading into 2027 and maintained a measured view on pipeline execution.BofA said it expects updates on the pricing and adoption durability of Pavblu to treat certain retinal eye conditions amid growing competition. It added that successive biosimilar launches could offset erosion in mature products.The firm reiterated its underperform rating on the stock and increased its price target to $328 per share from $317.Price: 415.34, Change: +0.47, Percent Change: +0.11","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","BBH":"VanEck Biotech ETF","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0058720904.USD":"联博国际健康护理基金A","PJP":"INVESCO PHARMACEUTICALS ETF","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BIB":"Ultra纳斯达克生物科","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","AMGN":"安进","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"美国银行证券表示，安进第三季度业绩应反映持续的商业势头","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TBXU":0.6,"AMGN":1.5,"PJP":0.6,"PBE":0.6,"BBH":0.6,"BIB":0.6,"IBBQ":0.6,"IBB":0.6},"content_text":"Amgen's (AMGN) Q3 results should reflect continued momentum across the company's growth portfolio and offer clarity on the anticipated sequential rise in operating expenses, BofA Securities said in a Monday research report.BofA said it expects Q3 adjusted EPS of $5.70 per share on revenue of $10.02 billion. The company is due to report Q3 results on Nov. 3.The brokerage said it also looks for clarity on the investment outlook heading into 2027 and maintained a measured view on pipeline execution.BofA said it expects updates on the pricing and adoption durability of Pavblu to treat certain retinal eye conditions amid growing competition. It added that successive biosimilar launches could offset erosion in mature products.The firm reiterated its underperform rating on the stock and increased its price target to $328 per share from $317.Price: 415.34, Change: +0.47, Percent Change: +0.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}